pyrroles has been researched along with vonoprazan in 249 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 135 (54.22) | 24.3611 |
| 2020's | 114 (45.78) | 2.80 |
| Authors | Studies |
|---|---|
| Arikawa, Y; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
| Hori, Y; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H | 1 |
| Hori, Y; Inatomi, N; Kajino, M; Matsukawa, J; Nishida, H; Takeuchi, T | 1 |
| Inatomi, N; Munson, K; Sachs, G; Shin, JM; Strugatsky, D; Tokhtaeva, E; Vagin, O | 1 |
| Hasuoka, A; Inatomi, N; Kajino, M; Kawamoto, M; Kondo, M; Tarui, N | 1 |
| Arikawa, Y; Hamada, T; Hasuoka, A; Hirase, K; Hori, Y; Imanishi, A; Inatomi, N; Kajino, M; Kondo, M; Kurasawa, O; Matsukawa, J; Nishida, H; Takagi, T; Takeuchi, T; Tarui, N | 1 |
| Ashida, K; Hibberd, M; Jenkins, H; Jenkins, R; Nishimura, A; Ogama, Y; Okamoto, H; Sakurai, Y; Warrington, S; Yoneyama, T | 1 |
| Garnock-Jones, KP | 1 |
| Sugano, K | 1 |
| Araki, T; Komura, E; Mori, Y; Nishimura, A; Okamoto, H; Sakurai, Y; Shiramoto, M | 1 |
| Ashida, K; Chiba, T; Hiramatsu, N; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E | 1 |
| Echizen, H | 1 |
| Lambrecht, NW; Marcus, EA; Munson, KB; Sachs, G; Scott, DR | 1 |
| Horio, A; Kamiya, K; Nishio, E; Tokura, Y | 1 |
| Inatomi, N; Matsukawa, J; Otake, K | 1 |
| Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E | 2 |
| Cao, N; Liu, L; Ma, X; Sun, L; Xiong, K; Zou, Q | 1 |
| Asahi, S; Jinno, F; Kondo, T; Teshima, K; Yoneyama, T | 1 |
| Asaka, M; Funao, N; Murakami, K; Nishimura, A; Sakurai, Y; Shiino, M | 1 |
| Inatomi, N; Kogame, A; Matsukawa, J; Tagawa, Y | 1 |
| Furuta, T; Hamaya, Y; Ichikawa, H; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M | 1 |
| Ishihara, S; Kawashima, K; Kinoshita, Y | 1 |
| Marcus, EA; Sachs, G; Scott, DR | 1 |
| Gotoda, T; Iwatsuka, K; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Kondo, T; Miwa, H; Oshima, T | 1 |
| Asahi, S; Bernards, A; Kawaguchi, N; Kogame, A; Kondo, T; Moriwaki, T; Morohashi, A; Nonaka, M; Tagawa, Y; Takeuchi, T; Yamasaki, H | 1 |
| Fukui, H; Inatomi, N; Karashima, M; Nishida, H; Otake, K; Otsuka, K; Sakurai, Y; Tagawa, Y; Yamasaki, H | 1 |
| Hayashi, Y; Kondo, Y; Lefor, AK; Nomoto, H; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Asahi, S; Hirabayashi, H; Kawaguchi, N; Moriwaki, T; Morohashi, A; Nonaka, M; Takahashi, J; Yamasaki, H | 1 |
| Hasegawa, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakurai, Y; Shiino, M | 1 |
| Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K | 1 |
| Arai, M; Ishigami, H; Kasamatsu, S; Katsuno, T; Maruoka, D; Matsumura, T; Nakagawa, T; Okimoto, K; Saito, K; Taida, T; Yokosuka, O | 1 |
| Fukui, K; Hayakawa, Y; Hirata, Y; Isomura, Y; Ito, Y; Koike, K; Matsuo, K; Mochizuki, S; Niikura, R; Okamoto, M; Omae, T; Seto, M; Shichijo, S; Sugimoto, T; Suzuki, H; Suzuki, N; Takano, N; Togo, G; Watabe, H; Yamada, A; Yamamoto, S | 1 |
| Horii, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakata, Y; Sakurai, Y; Shiino, M | 1 |
| Fujita, M; Graham, DY; Haruma, K; Ishii, M; Kamada, T; Katsumata, R; Matsumoto, H; Murao, T; Nakato, R; Shiotani, A | 1 |
| Adachi, K; Ebi, M; Funaki, Y; Goji, S; Izawa, S; Kasugai, K; Noda, H; Noguchi, S; Ogasawara, N; Sasaki, M; Tamura, Y; Yamamoto, S; Yoshimine, T | 1 |
| Kajihara, Y; Mizuki, I; Shimoyama, T | 1 |
| Mizukami, K; Murakami, K | 1 |
| Miwa, H; Mori, Y; Nishimura, A; Sakaki, N; Sakurai, Y; Takanami, Y; Tatsumi, T; Uedo, N; Watari, J | 1 |
| Jenkins, H; Jenkins, R; Patat, A | 1 |
| Arase, Y; Deguchi, R; Dekiden, M; Mine, T; Miyakita, H; Myojin, K; Ogimi, T; Shimada, H; Shiraishi, K | 1 |
| Eguchi, T; Fujita, M; Fukuchi, T; Hashimura, H; Kanamori, A; Kano, C; Koizumi, A; Matsumoto, K; Momose, K; Okada, A; Shimoyama, K; Tsujimae, M; Yamashita, H | 1 |
| Arai, E; Fukui, H; Fukui, S; Kondo, T; Kono, T; Miwa, H; Ohda, Y; Okugawa, T; Oshima, T; Taki, M; Takimoto, M; Tomita, T; Tozawa, K; Watari, J; Yamasaki, T | 1 |
| Kato, M; Mabe, K; Nakagawa, S; Ono, S; Sakamoto, N | 1 |
| Hanada, Y; Hoshihara, Y; Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kawagoe, T; Kawami, N; Nomura, T; Sano, H; Takenouchi, N; Umezawa, M | 1 |
| Astruc, B; Jenkins, H; Jenkins, R | 1 |
| Hasuda, K; Hattori, M; Ido, Y; Okuda, A; Sakurai, K; Suda, H; Takeichi, T | 1 |
| Izumi, M; Kato, S; Kato, Y; Masui, Y; Nakajima, A; Tanida, E; Tsuchiya, I | 1 |
| Fujisawa, T; Horiuchi, A; Imai, R; Kimura, T; Kiyosawa, K; Kubota, D; Maruyama, M; Matsuda, Y; Miyajima, M; Mori, H; Tanaka, N; Tokutake, K; Wada, S | 1 |
| Jung, YS; Kim, EH; Park, CH | 1 |
| Fujiwara, Y; Hasegawa, T; Inoue, A; Ishizu, H; Iwakura, N; Nakahara, K; Okuyama, M; Oyama, M; Satoh, H | 1 |
| Hu, Y; Lu, NH; Zhu, Y | 2 |
| Amano, H; Arima, I; Fukuchi, T; Ikeda, A; Inokuchi, Y; Ishii, Y; Iwase, S; Iwata, Y; Kanno, M; Kawana, I; Kokawa, A; Komatsu, K; Kondo, M; Kunishi, Y; Kuwashima, H; Maeda, S; Miwa, H; Morimoto, M; Naito, M; Oka, H; Okazaki, H; Saito, T; Sanga, K; Sasaki, T; Shibata, W; Sue, S; Takahashi, D; Tamura, T; Terada, M | 1 |
| Liu, X; Qiao, Y; Tang, X; Wang, Q; Xu, Y; Yue, X; Zhang, R; Zhang, Y; Zhao, J | 1 |
| Blandizzi, C; Bodini, G; de Bortoli, N; Marabotto, E; Marchi, S; Martinucci, I; Savarino, E; Savarino, V | 1 |
| Eguchi, T; Fujita, M; Hashimura, H; Kanamori, A; Kano, C; Matsumoto, K; Momose, K; Obata, D; Okada, A; Tsujimae, M; Yamashita, H; Yoshizaki, T | 1 |
| Ando, K; Fujinaga, A; Fujiya, M; Goto, M; Ichiishi, E; Ito, T; Kashima, S; Kawamoto, T; Kohgo, Y; Moriichi, K; Nomura, Y; Okumura, T; Otake, T; Sato, K; Sato, T; Sugano, H; Tanabe, H; Ueno, N; Utsumi, T; Yanagawa, N | 1 |
| D'Angelo, F; Frossard, JL; Gkouvatsos, K; Guglielmi, S | 1 |
| Kim, EH; Park, CH | 1 |
| Fujibayashi, S; Fujiya, M; Goto, T; Kashima, S; Moriichi, K; Nomura, Y; Okumura, T; Sakatani, A; Sasajima, J; Tanaka, K; Ueno, N | 1 |
| Furuta, T; Hamaya, Y; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Umemura, K; Uotani, T; Yamade, M | 1 |
| Dong, SQ; Singh, TP; Wang, HL; Wei, X; Yao, H | 1 |
| Gisbert, JP; Lamarque, D; O'Connor, A; O'Morain, C | 1 |
| Furuta, T; Hamaya, Y; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Uotani, T; Yamade, M | 1 |
| Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K | 1 |
| Gotoda, T; Ikehara, H; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Chen, X; Li, M; Liu, A; Liu, Y; Luo, Z; Qiu, Y; Wang, G; Wang, H; Zhai, H; Zhang, H | 1 |
| Hayashi, Y; Lefor, AK; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 2 |
| Iwakiri, K | 1 |
| Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K | 1 |
| Taha, AS | 1 |
| Fushimi, S; Horikawa, Y; Kato, Y; Mimori, N; Mizutamari, H; Okubo, S; Sato, S | 1 |
| Kato, M; Kudo, T; Matsuno, Y; Miyamoto, S; Ono, S; Sakamoto, N; Shimizu, Y | 1 |
| Hiraga, J; Kagami, Y; Suzuki, N; Takagi, Y; Tsuzuki, T; Uematsu, N | 1 |
| Arima, I; Kaneko, H; Komatsu, K; Kondo, M; Kuwashima, H; Maeda, S; Naito, M; Nakao, S; Ogushi, M; Sasaki, T; Shibata, W; Sue, S; Tamura, T | 1 |
| Ishimura, N; Kinoshita, Y | 1 |
| Fujisaki, J; Hirasawa, T; Horiuchi, Y; Ishiyama, A; Muramatsu, Y; Sasaki, Y; Tsuchida, T; Yamasaki, A; Yoshio, T | 1 |
| Dore, MP; Graham, DY | 1 |
| Ashida, K; Furuta, T; Harada, S; Higuchi, K; Hongo, Y; Kawaguchi, S; Kojima, Y; Ota, K; Ozaki, H; Sakaguchi, M; Sakamoto, H; Takahashi, Y; Takeuchi, T; Tokioka, S; Tominaga, K | 1 |
| Fukumoto, K; Higashino, K; Higuchi, K; Kojima, K; Kojima, Y; Sakaguchi, M; Sakamoto, H; Sanomura, M; Takata, K; Takeuchi, T; Tominaga, K | 1 |
| Harada, S; Higuchi, K; Hirai, A; Kawaguchi, S; Kojima, Y; Ota, K; Takahashi, Y; Takeuchi, T; Tokioka, S; Tominaga, K | 1 |
| Hanada, Y; Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kaise, M; Kawami, N; Koizumi, E; Takenouchi, N; Umezawa, M | 1 |
| Talebi Bezmin Abadi, A; Yamaoka, Y | 1 |
| Moss, SF; Pellicano, R; Saracco, GM; Zagari, RM; Zhang, S | 1 |
| Czerniak, R; Nishihara, M | 1 |
| Fujishiro, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shinozaki, T; Takahashi, A; Takeuchi, Y; Yamada, A | 1 |
| Abe, K; Fujiyoshi, Y; Irie, K; Nakanishi, H; Suzuki, H | 1 |
| Cai, M; He, X; Li, T; Qiao, H; Yue, P | 1 |
| Furuta, T; Kagami, T | 1 |
| Fukui, H; Horikawa, T; Li, M; Miwa, H; Oshima, T; Tomita, T; Tozawa, K; Watari, J | 1 |
| Akasaka, T; Arao, M; Fukui, K; Hamada, K; Hanaoka, N; Higashino, K; Iishi, H; Ishihara, R; Iwatsubo, T; Kanesaka, T; Kato, M; Matsuura, N; Nakahira, H; Okada, H; Shichijo, S; Shimokawa, T; Suzuki, S; Takeuchi, Y; Tonai, Y; Uedo, N; Yamamoto, S; Yamasaki, Y | 1 |
| Ando, K; Fujiya, M; Ichiishi, E; Ishizuka, A; Kohgo, Y; Nomura, Y; Ohta, K; Okumura, T; Otake, T; Satoh, K; Tanabe, H; Yoshino, K | 1 |
| Ishihara, S; Ishimura, N; Kinoshita, Y | 1 |
| Jaruvongvanich, V; Poonsombudlert, K; Ungprasert, P | 1 |
| Hayashi, Y; Kobayashi, Y; Lefor, AK; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Hayashi, Y; Kawarai Lefor, A; Kobayashi, Y; Miura, Y; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Kim, EH; Lee, JG; Nam, E; Park, CH; Park, SW | 1 |
| Endo, H; Fujimoto, K; Hara, M; Hidaka, H; Kawachi, K; Matsunaga, T; Nakano, R; Sakata, Y; Shimoda, R; Takara, Y; Tsuruoka, N | 1 |
| Inatomi, N; Matsukawa, J; Nishida, H; Tsukimi, Y | 1 |
| Eto, T; Ichida, T; Kusano, F; Sakai, Y; Ueyama, S | 1 |
| Choi, G; Kang, H; Kim, BJ; Kim, JG | 2 |
| Fujie, S; Hasuda, K; Hattori, M; Hirano, M; Ito, K; Murao, T; Okuda, A; Sakurai, K; Suda, H; Takeichi, T; Tsuruta, K | 1 |
| Haruma, K; Kawamoto, H; Manabe, N; Suehiro, M | 1 |
| Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J | 1 |
| Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kaise, M; Kawami, N; Tanabe, T; Umezawa, M | 1 |
| Kokubo, H; Liu, K | 1 |
| Fukuba, N; Ishitobi, H; Kinoshita, Y; Kobayashi, Y; Komazawa, Y; Kusunoki, M; Nagaoka, M; Shizuku, T; Takahashi, Y; Yuki, M | 1 |
| Chen, QT; He, HS; Li, BY; Shi, B; Shi, J; Song, CY | 1 |
| Meng, CX; Takagi, T; Tian, YS; Zhou, Y | 2 |
| Akazawa, Y; Asaoka, D; Hojo, M; Komori, H; Matsumoto, K; Nagahara, A; Takeda, T; Ueyama, H; Watanabe, S; Yao, T | 1 |
| Funakoshi, R; Furihata, K; Ito, K; Kudo, T; Kusuhara, H; Tomoda, Y | 1 |
| Deguchi, H; Higuchi, K; Igarashi, A; Miyazaki, H; Takeuchi, T; Tango, T; Teng, L; Uda, A | 1 |
| Akiyama, J; Hisada, Y; Hosaka, H; Imbe, K; Kawamura, O; Kojima, Y; Kuribayashi, S; Kusano, M; Moriyasu, S; Nagata, N; Okubo, H; Shimoyama, Y; Uemura, N; Watanabe, K; Yamada, M; Yokoi, C | 1 |
| Hatakeyama, H; Noguchi, Y; Seko, T; Tachi, T; Teramachi, H | 1 |
| Deguchi, H; Igarashi, A; Miwa, H; Tango, T; Teng, L; Uda, A | 1 |
| Nishihara, M | 1 |
| Fujimori, S; Horikawa, Y; Iijima, K; Ishii, H; Koizumi, S; Mimori, N; Onochi, K; Sugawara, K; Tsuji, T; Watanabe, H | 1 |
| Choi, CW; Kang, DH; Kim, HW; Kim, SJ; Ko, J; Park, SB | 1 |
| Goto, O; Hanada, Y; Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kaise, M; Kawami, N; Takenouchi, N; Tanabe, T | 1 |
| Hinoue, Y; Kamiyamamoto, S; Mizuno, H; Nishino, M; Yamada, K | 1 |
| Habu, Y | 1 |
| Lyu, QJ; Pu, QH; Zhang, J; Zhong, XF | 1 |
| Akasaka, T; Ishida, H; Kato, S; Kawamoto, Y; Mori, K | 1 |
| Kiyotoki, S; Nishikawa, J; Sakaida, I | 1 |
| Fukui, K; Hayashi, S; Higaki, Y; Inada, M; Matsubara, T; Mukai, K; Nakajima, S; Nakamatsu, D; Nishida, T; Okamoto, A; Osugi, N; Sugimoto, A; Takahashi, K; Tomita, R; Tsujii, Y; Yamamoto, M | 1 |
| Deguchi, H; Higuchi, K; Igarashi, A; Takeuchi, T; Uda, A; Yokoya, Y | 1 |
| Chen, M; Chong, CF; Chun, HJ; Dai, N; Fei, G; Funao, N; Goh, KL; Sheu, BS; Xiao, Y; Zhang, S; Zhou, W | 1 |
| Feng, BC; Li, LX; Li, YQ; Liu, C; Zhang, Y; Zuo, XL | 1 |
| Dohi, O; Hara, T; Inada, Y; Inoue, K; Itoh, Y; Iwai, N; Kagawa, K; Komaki, T; Konishi, H; Naito, Y; Oka, K; Okuda, T; Tsuji, T | 1 |
| Argueta, EA; Moss, SF | 1 |
| Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Tani, S; Umemura, K; Uotani, T; Yamade, M | 1 |
| Al-Jawabri, NA; Albohy, A; Aldalaien, SM; Disi, AM; Ebada, SS; Proksch, P; Youssef, FS | 1 |
| Tytgat, GNJ | 1 |
| Chinen, T; Hamada, S; Ihara, E; Ikeda, H; Muta, K; Ogawa, Y; Ogino, H; Tanaka, Y | 1 |
| Hotta, K; Imai, K; Ishiwatari, H; Ito, S; Kakushima, N; Kawata, N; Kishida, Y; Matsubayashi, H; Murai, K; Ono, H; Takizawa, K; Tanaka, M; Yabuuchi, Y; Yoshida, M | 1 |
| Kato, M; Kimura, N; Kubo, K; Mabe, K; Matsuda, S; Tsuda, M | 1 |
| Hoshikawa, Y; Hoshino, S; Ishikawa, Y; Iwakiri, K; Kaise, M; Kawami, N; Koeda, M; Momma, E; Takenouchi, N; Tanabe, T | 1 |
| Kishibuchi, M; Takada, K; Yoshioka, K | 1 |
| Fujiwara, Y; Hattori, M; Higashimori, A; Hosomi, S; Kamata, N; Kosaka, S; Matsumoto, Y; Nadatani, Y; Nagami, Y; Nakata, A; Otani, K; Suda, W; Taira, K; Tanaka, F; Tanigawa, T; Watanabe, T; Yamagami, H | 1 |
| Araki, T; Ashida, K; Iwakiri, K; Kinoshita, Y; Kudou, K; Miyagi, T; Sakurai, Y; Takabayashi, N | 1 |
| Barberio, B; Ghisa, M; Savarino, E; Savarino, V | 1 |
| Adachi, K; Ebi, M; Funaki, Y; Hijikata, Y; Izawa, S; Kasugai, K; Ogasawara, N; Sasaki, M; Shinmura, T; Yamaguchi, Y | 1 |
| Asahina, A; Kikuchi, S; Nobeyama, Y; Saeki, H | 1 |
| Hayashi, Y; Kobayashi, Y; Lefor, AK; Osawa, H; Sakamoto, H; Shinozaki, S; Yamamoto, H | 1 |
| Fujimoto, K; Fujiwara, Y; Funaki, Y; Furuta, T; Harada, S; Higuchi, K; Higuchi, T; Kagami, T; Kasugai, K; Kawamura, O; Kojima, Y; Kusano, M; Murata, M; Okada, H; Okamoto, Y; Ota, K; Sawada, A; Sugimoto, M; Suzuki, T; Takeuchi, T; Tamura, Y; Tanaka, F; Uotani, T; Yamade, M | 1 |
| Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Tani, S; Umemura, K; Yamade, M | 1 |
| Abe, Y; Asano, N; Asanuma, K; Hatta, W; Imatani, A; Koike, T; Masamune, A; Nakagawa, K; Okata, T; Saito, M; Uno, K | 1 |
| Cheng, Y; Dai, Y; Jiang, H; Kou, F; Li, J; Li, X; Liu, J; Lu, Q; Tan, X; Xie, C | 1 |
| Gotoh, Y; Honda, S; Ishibashi, E; Kagawa, K; Murakami, K; Nakaya, T; Noguchi, C | 1 |
| Deguchi, H; Sugano, K; Tsujita, K; Uda, A | 1 |
| Fujioka, Y; Hashiguchi, K; Imamura, I; Kakiuchi, T; Kawakubo, H; Matsuo, M; Mizoe, A; Nakayama, A; Okuda, M; Yamaguchi, D; Yamamoto, K | 1 |
| Mori, H; Suzuki, H | 1 |
| Ando, T; Handa, O; Horie, R; Imamoto, E; Itoh, Y; Murakami, T; Ose, T; Sendo, R; Suzuki, N | 1 |
| Miwa, H; Oshima, T | 1 |
| Doi, A; Matsueda, K; Mizuno, M; Mouri, H; Nishimura, N; Okada, H; Shimodate, Y; Takayama, H; Takezawa, R; Yamamoto, S | 1 |
| Chen, F; Geng, P; Jiang, H; Liu, B; Meng, D; Shen, J; Wang, B; Wang, S; Zhou, Q; Zhou, Y | 1 |
| Dohi, O; Fukui, A; Horie, R; Horii, Y; Ishida, T; Itoh, Y; Majima, A; Naito, Y; Tomatsuri, N; Tomie, A; Tsuji, T; Yagi, N; Yamada, N; Yamada, S; Yasuda, T; Zen, K | 1 |
| Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shichijo, S; Yamada, A | 1 |
| Gotoda, T; Horii, T; Ichijima, R; Ikehara, H; Kusano, C; Suzuki, S | 1 |
| Abe, Y; Asano, N; Fujishima, F; Hatta, W; Imatani, A; Jin, X; Kanno, T; Koike, T; Masamune, A; Nakagawa, K; Saito, M; Uno, K | 1 |
| Graham, DY; Lu, H; Shiotani, A | 1 |
| Akiyama, J; Cho, H; Hisada, Y; Iwata, E; Kawazoe, M; Kimura, K; Kobayakawa, M; Komori, S; Mishima, S; Nagata, N; Okahara, K; Okubo, H; Shimada, T; Shimomura, A; Shiroma, S; Takasaki, Y; Uemura, N; Watanabe, K; Yanagisawa, N; Yokoi, C | 1 |
| Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY | 1 |
| Fujiwara, Y; Hosomi, S; Kamata, N; Kuzumoto, T; Nadatani, Y; Nagami, Y; Otani, K; Sawada, A; Taira, K; Tanaka, F; Tanigawa, T; Watanabe, T | 1 |
| Kagawa, S; Kobara, H; Masaki, T; Nishiyama, A; Nishiyama, N | 1 |
| Fujino, T; Hiratsuka, T; Kato, Y; Miwa, W; Sato, K | 2 |
| Eguchi, T; Fujinami, M; Ikeoka, S; Inoue, K; Katayama, N; Matsuda, T; Matsumoto, M; Momose, K; Morisawa, T; Noda, M; Okada, A; Sako, T; Takagi, M; Yoshizaki, T | 1 |
| Fukuhara, T; Furukawa, Y; Hatsushika, Y; Kohno, T; Miyaki, E; Mori, N; Mouri, R; Ochi, H; Okanobu, H; Okazaki, A; Sakano, A; Takaki, S; Tsuji, K; Urabe, A; Yamashita, Y | 1 |
| Hoshikawa, Y; Hoshino, S; Iwakiri, K; Kawami, N | 1 |
| Hosohata, K; Inada, A; Iwanaga, K; Kambara, H; Nakatsuji, T; Niinomi, I; Oyama, S; Ueno, S; Wakabayashi, T | 1 |
| Bardou, M; Ben Ghezala, I; Luu, M | 1 |
| Graham, DY; Howden, CW | 1 |
| Fujioka, Y; Hashiguchi, K; Imamura, I; Kakiuchi, T; Kawakubo, H; Okuda, M; Yamaguchi, D; Yamamoto, K | 1 |
| Hayasaka, J; Hoshihara, Y; Hoteya, S; Iizuka, T; Kikuchi, D; Matsui, A; Nomura, K; Ochiai, Y; Odagiri, H; Suzuki, Y; Tanaka, M; Udagawa, H; Ueno, M; Yamashita, S | 1 |
| Eto, H; Gotoda, T; Ichijima, R; Ikehara, H; Ito, H; Kawabe, K; Kawamura, M; Kusano, C; Nakahara, M; Suzuki, S; Yoda, Y | 1 |
| Abe, H; Asano, N; Fujimori, K; Fushimi, K; Hatta, W; Imatani, A; Jin, X; Kanno, T; Koike, T; Masamune, A; Nakagawa, K; Nakamura, T; Nakaya, N; Ogata, Y; Saito, M; Tarasawa, K; Uno, K | 1 |
| Fukuda, S; Iijima, K; Koizumi, S; Matsuhashi, T; Shimodaira, Y; Takahashi, S; Watanabe, K | 1 |
| Fujiki, S; Gotoda, T; Ishiguro, M; Kawai, D; Kono, Y; Okanoue, S; Takemoto, K; Takenaka, R; Tsugeno, H | 1 |
| Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Miyajima, H; Osawa, S; Sugimoto, K; Suzuki, T; Tani, S; Uotani, T; Yamade, M | 1 |
| Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
| Higuchi, K; Hirata, Y; Kakimoto, K; Kinoshita, N; Kojima, Y; Koshiba, R; Miyazaki, T; Nakamura, S; Ota, K; Takeuchi, T; Tanaka, Y; Tawa, H; Tsujimoto, H; Ueda, Y | 1 |
| Deguchi, H; Fukuhara, S; Kamitani, T; Yamamoto, Y; Yamazaki, H | 1 |
| Gotoda, T; Horii, T; Ichijima, R; Ikehara, H; Kusano, C; Shibuya, H; Suzuki, S; Takano, C | 1 |
| Hakoda, A; Higuchi, K; Iwatsubo, T; Kanaoka, H; Kawaguchi, S; Kikutani, S; Kojima, Y; Nakada, K; Nishida, S; Osaka, N; Ota, K; Sasaki, S; Takeuchi, T; Takii, M; Tawa, H | 1 |
| Hashimoto, K; Okamoto, M; Wakunami, Y | 1 |
| Arai, M; Fukuda, K; Hasatani, K; Honda, T; Ikeya, T; Ishii, N; Kawai, T; Kiyotoki, S; Niikura, R; Nishida, T; Shiratori, Y; Sumiyoshi, T; Yoshida, N | 1 |
| Borody, TJ; Clancy, A; Dawson, MVM; Gunaratne, AW; Hamblin, H; Magat, AJMC; Tu, J | 1 |
| Aiba, M; Ito, S; Nagai, J; Tateno, T; Tsutsumi, Y | 1 |
| Araki, M; Ariyoshi, N; Kitagawa, M; Kitamura, S; Kobayashi, Y; Kubota, R; Maruyama, Y; Matsumoto, J; Mitsui, Y; Morinaga, H; Nasu, Y; Nishimura, S; Sadahira, T; Sekito, T; Sugiyama, H; Takeuchi, H; Tanabe, K; Wada, J; Wada, K; Watanabe, M; Watanabe, T; Watari, S; Yoshinaga, K | 1 |
| Hibberd, M; Howden, CW; Leifke, E; Mulford, DJ | 1 |
| Gotoda, T; Horii, T; Ichijima, R; Ikehara, H; Kusano, C; Ogura, K; Sugita, T; Suzuki, S; Takano, C | 1 |
| Gottlieb, M; Long, B | 1 |
| Antonioli, L; Barberio, B; Demarzo, MG; Fornai, M; Ghisa, M; Marabotto, E; Ribolsi, M; Savarino, E; Savarino, V; Zentilin, P; Zingone, F | 1 |
| Matsueda, K; Mizuno, M; Nishimura, N | 1 |
| Chan, FKL; Lui, RN | 1 |
| Bunchorntavakul, C; Buranathawornsom, A | 1 |
| Isomoto, H; Kimura, R; Sugihara, T; Sugita, K; Yamamoto, O | 1 |
| Pinion, S | 1 |
| Facius, A; Howden, CW; Lahu, G; Leifke, E; Mulford, DJ; Scarpignato, C; Smith, N | 1 |
| Hidaka, Y; Imai, T; Inaba, T; Kagawa, T; Omae, K; Tanaka, S | 1 |
| Demura, M; Esaka, N; Fujii, H; Hamada, H; Harada, N; Hirai, Y; Inoue, S; Kagaya, T; Kato, M; Kubo, K; Kuwai, T; Mabe, K; Matsuda, S; Matsumoto, M; Mori, H; Sakakibara, Y; Sasaki, Y; Toyokawa, T; Watanabe, N; Yamashita, H | 1 |
| Jang, IJ; Kim, B; Kim, S; Kim, Y; Lee, S; Park, SS; Song, GS; Yang, E; Yu, KS | 1 |
| An, H; He, Y; Huang, T; Jiang, Z; Li, S; Lin, H; Yang, C; Yuan, J | 1 |
| Howden, CW; Hunt, B; Laine, L; Leifke, E; Mulford, DJ; Sharma, P; Smith, N | 1 |
| Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S | 1 |
| Furuta, T; Hamaya, Y; Higuchi, T; Iwaizumi, M; Kagami, T; Osawa, S; Sugimoto, K; Takahashi, S; Tamura, S; Tani, S; Uotani, T; Yamade, M | 1 |
| He, C; Hu, Y; Li, NS; Lu, NH; Ouyang, YB; Peng, C; Shu, X; Xie, C; Xie, Y; Xu, X; Zhu, Y; Zhu, ZH | 3 |
| Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T | 1 |
| Ang, D; Ang, TL; Chan, YH; Koo, SH; Krishnasamy-Balasubramanian, JK; Kumar, R; Kwek, AB; Li, JW; Lin, KW; Ong, PJ; R, R; Soon, GH; Tan, CK; Tan, TY; Tan, Y; Tan, YJ; Wong, YJ | 1 |
| Eltukhi, WE; Hassan, YF; Salman, BI; Saraya, RE | 1 |
| Chey, WD; Howden, CW; Hunt, BJ; Laine, L; López, LJ; Mégraud, F | 1 |
| Cai, JP; Dai, DP; Geng, PW; Hong, Y; Luo, QF; Shi, JH; Wang, SH; Wang, YR; Xu, X; Zhao, FL; Zhou, Q; Zhou, S; Zhou, YF | 1 |
| Hu, Y; Lu, NH; Ouyang, Y; Wang, M; Xu, YL; Zhu, Y | 1 |
| Iihara, H; Ishida, M; Kawazoe, H; Kumada, K; Naito, J; Nonaka, Y; Okura, H; Sakai, H; Sano, M; Shimizu, M; Suzuki, A; Tsuchiya, M; Watanabe, D | 1 |
| Fallone, CA | 1 |
| Graham, DY | 1 |
| Cheng, H; Gao, W; Li, Y; Teng, G; Wang, C; Xu, Y | 1 |
| Hu, Y; Lu, NH | 1 |
| Ang, D | 1 |
| Cheng, X; Han, T; Jin, R; Li, J; Li, K | 1 |
| Bao, Y; Cai, L; Gu, Y; Li, X; Yang, T; Zhang, Z | 1 |
| Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K | 1 |
| Ren, C; Yang, M; Yang, Z | 1 |
| DeVault, K; Hunt, B; Katz, P; Laine, L; Lowe, J; Mitev, S; Spechler, S | 1 |
| Chen, D; Gong, H; Han, D; Liu, C; Liu, S; Zhu, X | 1 |
| Aizawa, F; Ando-Matsuoka, R; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Maruo, A; Miyata, K; Niimura, T; Sakaguchi, S; Sakajiri, Y; Sawada, R; Shibata, T; Takaoka, M; Yagi, K; Yamanishi, Y; Zamami, Y | 1 |
| Hu, W; Sun, Y; Yue, L | 1 |
| Liu, L; Nahata, MC | 1 |
| Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL | 1 |
| Facius, A; Howden, CW; Hunt, R; Lahu, G; Leifke, E; Mulford, DJ; Scarpignato, C | 1 |
| Almenoff, J | 1 |
| Gatta, L | 1 |
| Adler, DG; Bapaye, J; Chandan, OC; Chandan, S; Deliwala, S; Dhindsa, B; Facciorusso, A; Kassab, LL; Mohan, BP; Ramai, D | 1 |
| Al Asadi, H; Crawford, CV; Edelmuth, RCL; Fahey, TJ; Finnerty, BM; Greenberg, JA; Grier, A; Miranda, I; Najah, H; Riascos, MC; Zarnegar, R | 1 |
| Bai, G; Gao, Y; He, J; Sun, Y; Wang, J | 1 |
| Armstrong, D; Fass, R; Harris, T; Hunt, B; Leifke, E; Sharma, P; Smith, N; Vaezi, M; Yadlapati, R | 1 |
| Armstrong, D; Fass, R | 1 |
| Kahrilas, PJ | 1 |
| Bai, T; Hou, X; Liu, X; Wang, D; Xu, Z; Zhou, D | 1 |
47 review(s) available for pyrroles and vonoprazan
| Article | Year |
|---|---|
Vonoprazan: first global approval.
Topics: Animals; Drug Approval; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2015 |
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Topics: Administration, Oral; Animals; Biological Availability; Cytochrome P-450 CYP2C19; H(+)-K(+)-Exchanging ATPase; Humans; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2016 |
[Pharmacological and clinical profiles of a novel potassium-competitive acid blocker, vonoprazan fumarate (Takecab(®) 10 mg and 20 mg)].
Topics: Animals; Clinical Trials as Topic; Gastric Acid; Humans; Potassium; Potassium Channel Blockers; Pyrroles; Stomach Diseases; Sulfonamides | 2015 |
Gastroesophageal reflux disease-related and functional heartburn: pathophysiology and treatment.
Topics: Esophageal pH Monitoring; Esophagus; Gastric Acidity Determination; Gastroesophageal Reflux; Heartburn; Humans; Mucous Membrane; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
Topics: Gastrointestinal Agents; Gastrointestinal Diseases; Humans; Hydrogen-Ion Concentration; Pyrroles; Sulfonamides | 2016 |
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance | 2017 |
Vonoprazan fumarate for the management of acid-related diseases.
Topics: Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2017 |
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Remission Induction; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2017 |
[Gastroenterology and hepatology in 2016].
Topics: Biosimilar Pharmaceuticals; Disease Eradication; Drug Resistance, Bacterial; Duodenal Ulcer; Gastroenterology; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; Sulfonamides | 2017 |
Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Topics: Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2017 |
Treatment of Helicobacter pylori infection 2017.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance; Drug Substitution; Esophagitis, Peptic; Gastroenterology; Humans; Japan; Life Style; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Severity of Illness Index; Societies, Medical; Sulfonamides; Treatment Outcome | 2017 |
Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy.
Topics: Adult; Chronic Disease; Eosinophilic Esophagitis; Female; Humans; Japan; Male; Middle Aged; Prevalence; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Helicobacter pylori therapy and clinical perspective.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Failure | 2018 |
Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.
Topics: Anti-Bacterial Agents; Clarithromycin; Clinical Protocols; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; Sulfonamides | 2018 |
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis.
Topics: Endoscopic Mucosal Resection; Humans; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Wound Healing | 2018 |
Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis.
Topics: Anti-Ulcer Agents; Endoscopic Mucosal Resection; Humans; Network Meta-Analysis; Odds Ratio; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Wound Healing | 2019 |
Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis.
Topics: Cytochrome P-450 CYP2C19; Esophagus; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Systematic Reviews as Topic | 2018 |
Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis.
Topics: Endoscopic Mucosal Resection; Humans; Peptic Ulcer; Postoperative Complications; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Sulfonamides; Treatment Outcome; Wound Healing | 2019 |
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Topics: Bayes Theorem; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Network Meta-Analysis; Patient Selection; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Wound Healing | 2019 |
Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis.
Topics: Blood Loss, Surgical; Endoscopic Mucosal Resection; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Ulcer | 2019 |
Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for
Topics: Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis.
Topics: Endoscopic Mucosal Resection; Humans; Postoperative Complications; Proton Pump Inhibitors; Pyrroles; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2019 |
Treatment of Helicobacter pylori.
Topics: Amoxicillin; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Prognosis; Proton Pump Inhibitors; Pyrroles; Risk Assessment; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2019 |
Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Recent progress in Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Probiotics; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Vitamins | 2020 |
Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2021 |
Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies.
Topics: Adult; Endoscopic Mucosal Resection; Humans; Observational Studies as Topic; Postoperative Complications; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Ulcer | 2020 |
Update on quinolone-containing rescue therapies for
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Evidence-Based Medicine; Fluoroquinolones; Gastroenterology; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Mutation; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance.
Topics: Amoxicillin; Antimicrobial Stewardship; Clarithromycin; Drug Resistance, Bacterial; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Failure; Treatment Outcome | 2021 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Development of white globe appearance lesions in the noncancerous stomach after vonoprazan administration: a report of two cases with a literature review.
Topics: Aged; Female; Humans; Male; Proton Pump Inhibitors; Pyrroles; Stomach; Stomach Neoplasms; Sulfonamides | 2021 |
Comparison of Treatment Regimens for Helicobacter pylori Infection.
Topics: Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2021 |
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders.
Topics: Helicobacter Infections; Humans; Proton Pump Inhibitors; Pyrroles; Respiratory Distress Syndrome; Sulfonamides | 2022 |
Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2022 |
Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Topics: Adult; Bayes Theorem; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Network Meta-Analysis; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2022 |
Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis.
Topics: Constipation; Diarrhea; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2023 |
Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Topics: Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2023 |
Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis.
Topics: Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
62 trial(s) available for pyrroles and vonoprazan
| Article | Year |
|---|---|
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Topics: Adult; Asian People; Dose-Response Relationship, Drug; Double-Blind Method; Gastric Acid; Gastrointestinal Agents; Half-Life; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nervous System Diseases; Potassium; Pyrroles; Sulfonamides; United Kingdom; White People; Young Adult | 2015 |
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
Topics: Adult; Cross-Over Studies; Esomeprazole; Gastric Acid; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Research Design; Sulfonamides | 2015 |
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Esophagitis; Female; Gastrins; Humans; Lansoprazole; Los Angeles; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2015 |
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Double-Blind Method; Esophagitis; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Wound Healing | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Topics: Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Healthy Volunteers; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Wound Healing | 2016 |
Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspirin; Cross-Over Studies; Drug Interactions; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Endoscopy; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2017 |
Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.
Topics: Adult; Area Under Curve; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Half-Life; Humans; Male; Pyrroles; Sulfonamides | 2017 |
Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the
Topics: Adult; Aged; Breath Tests; Drug Monitoring; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; Urease | 2017 |
Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Topics: Aged; Drug Resistance; Endoscopy; Esophageal Mucosa; Esophagitis, Peptic; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2017 |
Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects.
Topics: Adult; Demography; Dose-Response Relationship, Drug; Electrocardiography; Female; Healthy Volunteers; Humans; Least-Squares Analysis; Male; Pyrroles; Sulfonamides | 2017 |
Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial.
Topics: Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Esomeprazole; Female; Humans; Male; Postoperative Complications; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2017 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Single-Blind Method; Sulfonamides; Treatment Outcome | 2017 |
Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Topics: Aged; Aged, 80 and over; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sleep Wake Disorders; Sulfonamides; Treatment Failure | 2017 |
Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
Topics: Acetamides; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastric Acid; Gastric Acidity Determination; Gastrins; Gastroesophageal Reflux; Healthy Volunteers; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Piperidines; Proton Pump Inhibitors; Pyridines; Pyrroles; Sulfonamides; Young Adult | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence Trials as Topic; Female; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Pyrroles; Recurrence; Secondary Prevention; Single-Blind Method; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2018 |
Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
Topics: Endoscopy; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pyrroles; Sulfonamides | 2017 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Pyrroles; Recurrence; Secondary Prevention; Sulfonamides; Treatment Outcome | 2018 |
Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Topics: Aged; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Pro
Topics: Aged; Anti-Bacterial Agents; Breath Tests; Comparative Effectiveness Research; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; H(+)-K(+)-Exchanging ATPase; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Polymorphism, Genetic; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2018 |
Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Lansoprazole; Male; Middle Aged; Postoperative Complications; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2018 |
Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.
Topics: Aged; Esophagitis, Peptic; Fasting; Female; Gastrins; Humans; Japan; Maintenance Chemotherapy; Male; Middle Aged; Patient Satisfaction; Practice Guidelines as Topic; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Recurrence; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2018 |
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gastric Mucosa; Gastroesophageal Reflux; Heartburn; Humans; Incidence; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Treatment Outcome | 2018 |
Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
Topics: Aged; Endoscopic Mucosal Resection; Female; Hematemesis; Hemoglobins; Humans; Lansoprazole; Male; Melena; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2019 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection.
Topics: Aged; Aged, 80 and over; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; Esomeprazole; Female; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Quinolones; Severity of Illness Index; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Wound Healing | 2019 |
Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Topics: Adult; Aged; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Remission Induction; Self Report; Sulfonamides; Time Factors; Treatment Outcome | 2019 |
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2019 |
A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia.
Topics: Aged; Endoscopic Mucosal Resection; Female; Follow-Up Studies; Humans; Male; Postoperative Complications; Prognosis; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Wound Healing | 2019 |
Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Topics: Adult; Area Under Curve; Atovaquone; Chromatography, Liquid; Cytochrome P-450 CYP2C19; Drug Combinations; Esomeprazole; Humans; Male; Proguanil; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Tandem Mass Spectrometry; Triazines; Young Adult | 2019 |
Dose-related healing of artificial ulcers after endoscopic submucosal dissection using esomeprazole: A randomized controlled study.
Topics: Endoscopic Mucosal Resection; Esomeprazole; Female; Humans; Male; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Republic of Korea; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Ulcer; Wound Healing | 2019 |
Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
Topics: Aged; Drug Administration Schedule; Esophageal Mucosa; Esophagitis, Peptic; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2020 |
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Drug Administration Schedule; Esophagitis, Peptic; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Severity of Illness Index; Sulfonamides; Treatment Outcome; Wound Healing | 2020 |
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Middle Aged; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).
Topics: Adolescent; Adult; Antacids; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Acid; Gastric Juice; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Japan; Male; Polymorphism, Genetic; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Young Adult | 2020 |
Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Drug Therapy, Combination; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Probiotics; Pyrroles; Sulfonamides | 2020 |
Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study.
Topics: Esophagitis; Humans; Pilot Projects; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
Topics: Dissection; Endoscopic Mucosal Resection; Humans; Lansoprazole; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2021 |
Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia.
Topics: Cross-Over Studies; Female; Gastric Acid; Gastrins; Humans; Male; Pirenzepine; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Young Adult | 2021 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Comorbidity; Dose-Response Relationship, Drug; Esomeprazole; Female; Gastrins; Gastrointestinal Hemorrhage; Gastrointestinal Microbiome; Hematocrit; Hemoglobins; Humans; Intestinal Mucosa; Lactobacillales; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.
Topics: Administration, Oral; Cross-Over Studies; Food-Drug Interactions; Humans; Potassium; Pyrroles; Sulfonamides | 2022 |
Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Cross-Sectional Studies; Endoscopic Mucosal Resection; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Pyrroles; Stomach Ulcer; Sulfonamides | 2021 |
A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
Topics: Cross-Over Studies; Gastroesophageal Reflux; Humans; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Topics: Benzene Derivatives; Cross-Over Studies; Cytochrome P-450 CYP2C19; Esomeprazole; Gastric Acid; Humans; Hydrogen-Ion Concentration; Imidazoles; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.
Topics: Adult; Humans; Hydrogen-Ion Concentration; Lansoprazole; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neoplasm Recurrence, Local; Pyrroles; Sulfonamides | 2022 |
Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan.
Topics: Clopidogrel; Cross-Over Studies; Gastrins; Humans; Hydrogen-Ion Concentration; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter; Helicobacter Infections; Helicobacter pylori; Humans; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; United States | 2022 |
Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Fatty Acids, Volatile; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Pyrroles; RNA, Ribosomal, 16S; Sulfonamides | 2022 |
Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbiota; Proton Pump Inhibitors; Pyrroles; RNA, Ribosomal, 16S; Sulfonamides | 2022 |
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Topics: Adult; Esophagitis; Humans; Lansoprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2023 |
Long-term potassium-competitive acid blockers administration causes microbiota changes in rats.
Topics: Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Potassium; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rats; Rats, Wistar | 2023 |
Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2023 |
Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.
Topics: Gastroesophageal Reflux; Humans; Patient Preference; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
140 other study(ies) available for pyrroles and vonoprazan
| Article | Year |
|---|---|
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Dithiothreitol; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Imidazoles; In Vitro Techniques; Kinetics; Lansoprazole; Ligation; Male; Potassium; Proton Pump Inhibitors; Pylorus; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach; Sulfonamides; Swine | 2010 |
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cells, Cultured; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Potassium; Proton Pump Inhibitors; Pyrroles; Rabbits; Stomach; Sulfonamides | 2011 |
A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Cimetidine; Dogs; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Histamine; Histamine Agonists; Hydrogen-Ion Concentration; Lansoprazole; Male; Potassium; Proton Pump Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2011 |
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
Topics: Acridine Orange; Animals; Fluorescent Dyes; Gastroesophageal Reflux; H(+)-K(+)-Exchanging ATPase; HEK293 Cells; Humans; Models, Molecular; Molecular Targeted Therapy; Phosphorylation; Protein Binding; Proton Pump Inhibitors; Pyrroles; Software; Stereoisomerism; Stomach; Sulfonamides; Swine | 2011 |
High-throughput screening of potassium-competitive acid blockers.
Topics: Animals; H(+)-K(+)-Exchanging ATPase; High-Throughput Screening Assays; Proton Pump Inhibitors; Pyrroles; Small Molecule Libraries; Sulfonamides; Swine | 2012 |
Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB).
Topics: Animals; Anti-Ulcer Agents; Dogs; Enzyme Inhibitors; Fumarates; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2012 |
[Vonoprazan: a novel potassium-competitive acid blocker].
Topics: Clinical Trials as Topic; Gastric Acid; Gastroesophageal Reflux; Humans; Potassium Channel Blockers; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2015 |
The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
Topics: Animals; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Half-Life; Male; Parietal Cells, Gastric; Proton Pump Inhibitors; Pyrroles; Rabbits; Sulfonamides | 2015 |
Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
Identification, characterization, and high-performance liquid chromatography quantification of process-related impurities in vonoprazan fumarate.
Topics: Chromatography, High Pressure Liquid; Drug Contamination; Molecular Structure; Pyrroles; Sulfonamides | 2016 |
A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Linear Models; Male; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.
Topics: Animals; Autoradiography; Gastric Mucosa; Male; Proton Pump Inhibitors; Pyrroles; Rats; Sulfonamides; Tritium | 2016 |
Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
Vonoprazan: MarKed Competition for PPIs?
Topics: Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
Topics: Animals; Bile; Dogs; Feces; Proton Pump Inhibitors; Pyrroles; Rats; Sulfonamides; Tissue Distribution | 2017 |
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori.
Topics: Atrophy; Disease Eradication; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Stomach; Sulfonamides; Treatment Outcome | 2016 |
In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.
Topics: Cytochrome P-450 CYP2C19; Gastrointestinal Agents; Pyrroles; Sulfonamides | 2017 |
Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis.
Topics: Aged; Endoscopic Mucosal Resection; Esomeprazole; Female; Follow-Up Studies; Gastroscopy; Humans; Male; Postoperative Complications; Propensity Score; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2017 |
Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Feasibility Studies; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2016 |
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; RNA, Ribosomal, 23S; Sulfonamides; Treatment Outcome; Urea | 2016 |
A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Remission Induction; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2016 |
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides | 2017 |
Effects of vonoprazan on intractable non-steroidal anti-inflammatory drug-induced ulcers that cannot be controlled with conventional proton pump inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lansoprazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Stomach Ulcer; Sulfonamides | 2017 |
Successful Eradication Therapy for Helicobacter pylori-positive Atrophic Gastritis at the Sixth Attempt: A Case Report.
Topics: Aged; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Pyrroles; Sulfonamides; Treatment Failure; Treatment Outcome | 2016 |
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Male; Metronidazole; Middle Aged; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Urea | 2017 |
Comparative study: Vonoprazan and proton pump inhibitors in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Patient Safety; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2017 |
The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Young Adult | 2017 |
Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Drug Stability; Japan; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stomach; Sulfonamides; Tandem Mass Spectrometry; Therapeutic Equivalency; Tissue Distribution | 2017 |
The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Topics: Aged; Aged, 80 and over; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Substitution; Electric Impedance; Esophageal Mucosa; Esophageal pH Monitoring; Esophagitis, Peptic; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Manometry; Middle Aged; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Time Factors | 2017 |
Vonoprazan-Based Helicobacter pylori Eradication Therapy: Time to Get Kompetitive?
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2017 |
Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis.
Topics: Abdominal Pain; Aged; Amoxicillin; Biopsy; Colitis; Colon; Colonoscopy; Female; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Hemorrhage; Humans; Klebsiella oxytoca; Metronidazole; Mucous Membrane; Pyrroles; Rare Diseases; Sulfonamides | 2017 |
Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
Topics: Adult; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Female; Genotype; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Sulfonamides; Young Adult | 2018 |
Development of a stability- indicating HPLC method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cost-Benefit Analysis; Drug Contamination; Drug Stability; Fumarates; Limit of Detection; Oxidation-Reduction; Proton Pump Inhibitors; Pyrroles; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Technology, Pharmaceutical; Time Factors | 2018 |
Vonoprazan, aspirin and NSAIDs: new era in acid inhibition and gastroprotection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
Topics: Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Japan; Lansoprazole; Logistic Models; Middle Aged; Multivariate Analysis; Postoperative Complications; Potassium; Propensity Score; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2018 |
Parietal Cell Protrusions and Dilated Oxyntic Glands from Use of Vonoprazan.
Topics: Adult; Biopsy; Endoscopy, Gastrointestinal; Gastric Mucosa; Gastroesophageal Reflux; Humans; Male; Parietal Cells, Gastric; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study.
Topics: Aged; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrroles; Retrospective Studies; Sulfonamides | 2018 |
Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Drug Substitution; Endoscopic Mucosal Resection; Female; Gastroscopy; Humans; Male; Middle Aged; Postoperative Complications; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Stomach; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2018 |
Update on the Use of Vonoprazan: A Competitive Acid Blocker.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Hemostasis, Endoscopic; Humans; Hydrogen-Ion Concentration; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2018 |
Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Esophagitis, Peptic; Female; Gastrins; Gastritis, Atrophic; Humans; Long-Term Care; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
CYP-Mediated Drug-Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Genotype; Prasugrel Hydrochloride; Pyrroles; Sulfonamides | 2018 |
Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
Topics: Adult; Aged; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Self Report; Sulfonamides; Treatment Outcome | 2018 |
Crystal structures of the gastric proton pump.
Topics: Amino Acid Sequence; Animals; Binding Sites; Cations, Monovalent; Crystallography, X-Ray; H(+)-K(+)-Exchanging ATPase; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Models, Molecular; Potassium; Protein Binding; Proton Pump Inhibitors; Protons; Pyrroles; Rabbits; Stomach; Sulfonamides; Swine | 2018 |
Embryo-fetal toxicity assessment of vonoprazan in rats and rabbits.
Topics: Animals; Dose-Response Relationship, Drug; Embryo, Mammalian; Female; Fetal Development; Fetal Growth Retardation; Fetal Weight; Fetus; Gestational Age; Injections, Intravenous; Maternal Exposure; No-Observed-Adverse-Effect Level; Placenta; Pregnancy; Proton Pump Inhibitors; Pyrroles; Rabbits; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Sulfonamides | 2018 |
Response to "CYP-Mediated Drug-Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan".
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Esomeprazole; Genotype; Prasugrel Hydrochloride; Pyrroles; Sulfonamides | 2018 |
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2018 |
Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?
Topics: Clinical Trials as Topic; Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Inhibitory Concentration 50; Japan; Potassium; Prevalence; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2018 |
Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
Topics: Aged; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proton Pump Inhibitors; Pyrroles; Quality of Life; Recurrence; Retrospective Studies; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Wound Healing | 2018 |
Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
Topics: Aged; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Smoking; Sulfonamides; Treatment Failure | 2019 |
[Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].
Topics: Drug Evaluation, Preclinical; Fumarates; Humans; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2018 |
Potassium-competitive acid blocker.
Topics: Drug Resistance; Esophagitis, Peptic; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2016 |
Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease.
Topics: Aged; Drug Administration Schedule; Female; Gastrins; Gastroesophageal Reflux; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Uncovering abnormal changes in logP after fluorination using molecular dynamics simulations.
Topics: 1-Butanol; 1-Octanol; Alkanes; Computer Simulation; Fluorine; Halogenation; Indoles; Models, Chemical; Molecular Dynamics Simulation; Pyrroles; Solvents; Sulfonamides; Thermodynamics; Water | 2019 |
Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2019 |
Vonoprazan versus proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: Protocol for meta-analysis of randomized controlled trials and observational studies.
Topics: Endoscopic Mucosal Resection; Epidemiologic Studies; Gastrointestinal Hemorrhage; Humans; Meta-Analysis as Topic; Postoperative Complications; Proton Pump Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Systematic Review as Topic; Time Factors | 2019 |
Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Topics: Aged; Aged, 80 and over; Drug Substitution; Esophageal pH Monitoring; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy.
Topics: Adult; Aged; Ambulatory Care Facilities; Cost-Benefit Analysis; Drug Costs; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Pharmacists; Proton Pump Inhibitors; Pyrroles; Quality of Life; Sulfonamides; Treatment Outcome | 2019 |
Inhibitory Effect of Vonoprazan on the Metabolism of [
Topics: Clopidogrel; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Microsomes, Liver; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Sulfonamides | 2019 |
Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2019 |
Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
Topics: Aged; Drug Resistance; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Female; Gastric Mucosa; Gastrins; Humans; Maintenance Chemotherapy; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Recurrence; Sulfonamides; Symptom Assessment; Time Factors | 2019 |
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Topics: Adult; Cost-Benefit Analysis; Drug Administration Schedule; Female; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Japan; Lansoprazole; Markov Chains; Pyrroles; Quality of Life; Sulfonamides | 2019 |
Gastric candidiasis developing after administration of potassium-competitive acid blocker.
Topics: Candidiasis; Humans; Male; Middle Aged; Pyrroles; Stomach Diseases; Sulfonamides | 2019 |
A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Packaging; Drug Therapy, Combination; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Propensity Score; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Topics: Computer Simulation; Cost-Benefit Analysis; Esomeprazole; Gastroesophageal Reflux; Humans; Japan; Markov Chains; Proton Pump Inhibitors; Pyrroles; Quality-Adjusted Life Years; Rabeprazole; Recurrence; Sulfonamides; Time Factors; Treatment Outcome | 2019 |
Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atherosclerosis; Cholesterol, HDL; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lipid Metabolism; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2019 |
Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
In vivo antiulcer activity, phytochemical exploration, and molecular modelling of the polyphenolic-rich fraction of Crepis sancta extract.
Topics: Animals; Anti-Ulcer Agents; Crepis; Gastric Mucosa; Male; Omeprazole; Phytochemicals; Phytotherapy; Plant Extracts; Polyphenols; Pyrroles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides | 2020 |
Highlights from Gastro Update Europe - Budapest June 26-27, 2019.
Topics: Celiac Disease; Clostridioides difficile; Colorectal Neoplasms; Endoscopy, Digestive System; Enterocolitis, Pseudomembranous; Foodborne Diseases; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Pancreatic Intraductal Neoplasms; Pancreatitis; Proton Pump Inhibitors; Pyrimidinones; Pyrroles; Sulfonamides; Tetrahydroisoquinolines | 2019 |
Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
Topics: Esophageal pH Monitoring; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Incidence of Delayed Bleeding among Patients Continuing Antithrombotics during Gastric Endoscopic Submucosal Dissection.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopic Mucosal Resection; Female; Fibrinolytic Agents; Humans; Male; Postoperative Hemorrhage; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Stomach Neoplasms; Stomach Ulcer; Sulfonamides; Time Factors | 2019 |
Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases.
Topics: Aged; Aged, 80 and over; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastroesophageal Reflux; Humans; Inflammation; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2020 |
Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Constriction, Pathologic; Drug Resistance; Esophagitis, Peptic; Female; Fibrinolytic Agents; Hemorrhage; Hernia, Hiatal; Humans; Kyphosis; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2020 |
Protein losing gastroenteropathy due to
Topics: Aged, 80 and over; Anti-Bacterial Agents; Diagnosis, Differential; Drug Therapy, Combination; Edema; Endoscopy; Female; Gastric Mucosa; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Hypoproteinemia; Protein-Losing Enteropathies; Pyrroles; Radionuclide Imaging; Sulfonamides; Technetium Tc 99m Aggregated Albumin; Treatment Outcome | 2019 |
Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii.
Topics: Animals; Disease Models, Animal; Dysbiosis; Fecal Microbiota Transplantation; High-Throughput Nucleotide Sequencing; Humans; Indomethacin; Injections, Intraperitoneal; Intestine, Small; Lactobacillus johnsonii; Male; Mice; Mice, Inbred C57BL; Proton Pump Inhibitors; Pyrroles; Rabeprazole; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Sulfonamides | 2019 |
Vonoprazan May Provide Better Results than PPIs in Helicobacter Pylori Eradication and Beyond - Is it Time for a Change?
Topics: Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2019 |
Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sex Factors; Stevens-Johnson Syndrome; Sulfonamides | 2020 |
Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicobacter pylori; Humans; Japan; Pyrroles; Sulfonamides | 2020 |
The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
Topics: Esophageal pH Monitoring; Gastroesophageal Reflux; Humans; Potassium; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2021 |
Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Male; Proton Pump Inhibitors; Pyrroles; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2020 |
Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study.
Topics: Aged; Asian People; Databases, Factual; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Japan; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2020 |
Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
How Does Vonoprazan Affect the Treatment of Erosive Esophagitis?
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Effect of Vonoprazan on Delayed Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasia among Antithrombotic Drug Users: A Single-Center, Single-Arm Prospective Observational Case Control Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Case-Control Studies; Endoscopy, Gastrointestinal; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Risk Factors; Stomach Neoplasms; Sulfonamides | 2020 |
Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Male; Microsomes, Liver; Pyrroles; Rats; Rats, Sprague-Dawley; Sulfonamides; Tandem Mass Spectrometry; Voriconazole | 2020 |
Clinical Outcomes of Vonoprazan-Treated Patients after Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Multicenter Observation Study.
Topics: Aged; Endoscopic Mucosal Resection; Female; Humans; Male; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2021 |
Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides | 2020 |
Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Students; Sulfonamides; Treatment Outcome | 2020 |
The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis.
Topics: Adenocarcinoma; Esophagitis, Peptic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis.
Topics: Eosinophilic Esophagitis; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Vonoprazan may cause white globe appearance in nonatrophic mucosa of stomach.
Topics: Humans; Mucous Membrane; Proton Pump Inhibitors; Pyrroles; Stomach; Sulfonamides | 2021 |
Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan.
Topics: Female; Gastric Mucosa; Humans; Incidence; Propensity Score; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides | 2021 |
Prevalence of behavioral disorders in patients with vonoprazan-refractory reflux symptoms.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Japan; Logistic Models; Male; Mental Disorders; Middle Aged; Prevalence; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2021 |
Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study.
Topics: Adverse Drug Reaction Reporting Systems; Humans; Japan; Pharmacovigilance; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Editorial: "Stardust gastric mucosa" - A novel and consistent marker of vonoprazan safety during follow-up?
Topics: Follow-Up Studies; Gastric Mucosa; Humans; Incidence; Propensity Score; Pyrroles; Risk Factors; Sulfonamides | 2021 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study.
Topics: Adolescent; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
Topics: Esophagectomy; Esophagitis, Peptic; Humans; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Body Size; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Prevention of delayed bleeding with vonoprazan in upper gastrointestinal endoscopic treatment.
Topics: Aged; Cohort Studies; Female; Hemorrhage; Humans; Japan; Male; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Upper Gastrointestinal Tract | 2021 |
Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
Topics: Aged; Case-Control Studies; Clostridium Infections; Female; Humans; Japan; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides | 2021 |
Marked reduction in the number of white globe appearance lesions in the noncancerous stomach after exchanging vonoprazan for esomeprazole treatment: a follow-up case report.
Topics: Aged; Esomeprazole; Female; Follow-Up Studies; Humans; Proton Pump Inhibitors; Pyrroles; Stomach; Sulfonamides | 2021 |
Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Interrupted Time Series Analysis; Japan; Pharmaceutical Preparations; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Administration of a standard dose of vonoprazan fumarate delays gastric emptying in Japanese healthy adults: a prospective clinical trial.
Topics: Gastric Emptying; Humans; Japan; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan.
Topics: Aged; Humans; Male; Potassium; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study.
Topics: Dissection; Endoscopic Mucosal Resection; Humans; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Stomach Neoplasms; Stomach Ulcer; Sulfonamides | 2022 |
Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Australia; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Convulsive Seizure Due to Hypomagnesemia Caused by Short-term Vonoprazan Intake.
Topics: Aged; Double-Blind Method; Female; Humans; Magnesium; Neoplasm Recurrence, Local; Proton Pump Inhibitors; Pyrroles; Seizures; Sulfonamides | 2022 |
Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Immunosuppressive Agents; Kidney Transplantation; Polymorphism, Genetic; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Tacrolimus | 2021 |
Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
Topics: Amoxicillin; Anti-Bacterial Agents; Body Weight; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Gastroduodenal Intussusception Due to Vonoprazan-induced Gastric Polyps.
Topics: Adenomatous Polyps; Gastric Fundus; Humans; Intussusception; Polyps; Pyrroles; Stomach Neoplasms; Sulfonamides | 2022 |
Vonoprazan-containing therapy has an
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2021 |
Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Esophagitis, Peptic; Humans; Pharmaceutical Preparations; Pyrroles; Scleroderma, Systemic; Sulfonamides; Ulcer | 2021 |
ACG 2021.
Topics: Adenoma; Antibodies, Monoclonal, Humanized; Circulating Tumor DNA; Colonoscopy; Colorectal Neoplasms; Congresses as Topic; Decontamination; Drug Therapy, Combination; Duodenoscopy; Eosinophilic Esophagitis; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure.
Topics: Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Ultra-Sensitive Fluorimetric Method for the First Estimation of Vonoprazan in Real Human Plasma and Content Uniformity Test.
Topics: Fluorometry; Humans; Pyrroles; Spectrometry, Fluorescence; Sulfonamides | 2022 |
Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo.
Topics: Animals; Chromatography, Liquid; Drug Interactions; Microsomes, Liver; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Sulfonamides; Tandem Mass Spectrometry | 2022 |
Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Nephritis, Interstitial; Pyrroles; Sulfonamides | 2022 |
The Current Role of Vonoprazan in Helicobacter pylori Treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Quality of Studies for Gastric pH Measurements With Vonoprazan.
Topics: Humans; Hydrogen-Ion Concentration; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in Ch
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Potassium; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome; Urease | 2022 |
Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
The influence of different proton pump inhibitors and potassium-competitive acid blockers on indomethacin-induced small intestinal injury.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; DNA, Ribosomal; Indomethacin; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Lipopolysaccharides; Mice; Omeprazole; Potassium; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides | 2022 |
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Topics: Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Esophagitis, Peptic; Genotype; Humans; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Secondary Prevention | 2023 |
Changes in gastric morphology during long-term use of vonoprazan compared to proton pump inhibitors.
Topics: Humans; Proton Pump Inhibitors; Pyrroles; Stomach; Sulfonamides | 2022 |
Vonoprazan May Induce Clostridium difficile Infection and Nephrotoxicity.
Topics: Clostridium Infections; Enterocolitis, Pseudomembranous; Humans; Pyrroles; Sulfonamides | 2023 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2022 |
Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
Topics: Endothelial Growth Factors; Humans; Molecular Docking Simulation; Neoplasms; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles | 2023 |
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
Topics: Esophagitis; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles | 2023 |
Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens.
Topics: Anti-Bacterial Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Rifabutin | 2023 |
Editorial: pharmacokinetic and pharmacodynamic model for vonoprazan-a step forward to precision medicine.
Topics: Humans; Precision Medicine; Pyrroles; Sulfonamides | 2023 |
Editorial: On-demand vonoprazan for NERD - when should it be 'demanded'? Authors' reply.
Topics: Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2023 |
Editorial: On-demand vonoprazan for NERD-when should it be 'demanded'?
Topics: Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2023 |